Home
CTNM
CTNM News

Latest Contineum Therapeutics Inc. Class A Common Stock (CTNM) News on January 22, 2025

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Business Wire

14 days ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

GlobeNewswire

16 days ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Business Wire

a month ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Business Wire

2 months ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Business Wire

2 months ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Simply Wall St.

2 months ago

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum Therapeutics to Attend Upcoming Investor Conferences

Business Wire

2 months ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

3 months ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Simply Wall St.

4 months ago

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Business Wire

5 months ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

5 months ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

6 months ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Business Wire

7 months ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Business Wire

8 months ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Business Wire

8 months ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Business Wire

8 months ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

8 months ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

10 months ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

Share on Social Networks: